Med
January 13, 2023
Natalie Gukasyan
12 citations
Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.
American Journal of Hospice and Palliative Medicine®
January 5, 2023
Kayla M Baker, Connie M Ulrich, Salimah H Meghani
2 citations
Background: Psilocybin-assisted therapies (PAT) are reemerging as a treatment for complex distress often prompting mystical experiences, enhanced meaning, and spiritual wellbeing. We sought to investigate how measures of spirituality are employed in experimental studies of PAT conducted with seriously ill adults. Methods: We included experimental studies of psilocybin conducted with seriously...
Journal of Psychoactive Drugs
2023
Zachary Herrmann, Mitch Earleywine, Joseph A. de Leo et al.
19 citations
Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions to psychedelic molecules are particularly interesting given how they covary with subsequent improvements associated with psychedelic-assisted treatments. Although links between subjective reactions and decreases in treatment-resistant clinical...
Neuropsychiatric Disease and Treatment
2023
Kwonmok Ko, Ben Carter, Anthony J. Cleare et al.
26 citations
In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...
Pharmaceuticals
December 28, 2022
Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al.
13 citations
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and...
Neurosurgery
December 8, 2022
Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi et al.
13 citations
After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and...
Oxford University Press eBooks
December 1, 2022
Stephen Ross, Anthony P. Bossis
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other serotonergic psychedelics delivered in...
Contemporary Clinical Trials
December 1, 2022
Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al.
24 citations
Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...
3 Biotech
December 1, 2022
Dominique Strauss, Soumya Ghosh, Zurika Murray et al.
13 citations
Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. Currently, the use of these mushrooms is illegal in most countries, but where their use is legal they are applied as self medication. Psilocybin and psilocin, two psychoactive alkaloids, are naturally synthesized by hallucinogenic mushrooms. The...
Current Psychiatry Reports
December 1, 2022
Natalie Gukasyan, Colleen C Schreyer, Roland R. Griffiths et al.
29 citations
A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may...